DURECT Corporation Reveals 2024 Financial Performance and Strategic Developments DURECT Corporation shares its financial results for the fourth quarter and full year 2024, highlighting advancements in larsucosterol development.

DURECT Corporation Reveals 2024 Financial Performance and Strategic Developments #United_States #Cupertino #Larsucosterol #AHFIRM_Trial #DURECT_Corporation

DURECT Corporation Publishes Promising Larsucosterol Findings for Alcohol-Associated Hepatitis DURECT Corporation has published significant Phase 2b trial data on Larsucosterol, showing promising results for treating Alcohol-Associated Hepatitis.

DURECT Corporation Publishes Promising Larsucosterol Findings for Alcohol-Associated Hepatitis #USA #DURECT #Cupertino #Larsucosterol #AHFIRM_Trial